Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Phase 1 Recruiting
18 enrolled
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
Phase 1 Recruiting
50 enrolled
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Phase 1 Recruiting
25 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
ELEPHAS-04
Recruiting
324 enrolled
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
Phase NA Recruiting
10 enrolled
ANCHOR
Phase 1 Recruiting
97 enrolled
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Phase 2 Recruiting
50 enrolled
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
Phase 1 Recruiting
106 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Phase 2/3 Recruiting
280 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
250 enrolled
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Phase 3 Recruiting
269 enrolled
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Recruiting
500 enrolled
ON-5001
Phase 1 Recruiting
168 enrolled
BrILliance
Phase 1/2 Recruiting
240 enrolled
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Phase NA Recruiting
26 enrolled
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Phase 1 Recruiting
56 enrolled
NBM-BMX-UM
Phase 1/2 Recruiting
36 enrolled
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Phase 1/2 Recruiting
754 enrolled
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
Phase 1 Recruiting
16 enrolled
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
Phase NA Recruiting
40 enrolled
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Phase 1 Recruiting
9 enrolled
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Phase 2/3 Recruiting
118 enrolled
AGADIR
Phase 2 Recruiting
247 enrolled
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Phase 1/2 Recruiting
3 enrolled
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/2 Recruiting
126 enrolled
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 1 Recruiting
40 enrolled
Cytophone
Phase NA Recruiting
180 enrolled
WoW
Phase NA Recruiting
2,486 enrolled
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Phase 1/2 Recruiting
168 enrolled
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Phase 1/2 Recruiting
160 enrolled
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Phase 1/2 Recruiting
358 enrolled
CER
Recruiting
15,000 enrolled
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
Phase 1 Recruiting
499 enrolled
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
Phase 2 Recruiting
40 enrolled